BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35146800)

  • 1. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
    Garreta Fontelles G; Pardo Pastor J; Grande Moreillo C
    Br J Clin Pharmacol; 2022 Aug; 88(8):3891-3895. PubMed ID: 35146800
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
    Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome.
    López Gutiérrez JC; Lizarraga R; Delgado C; Martínez Urrutia MJ; Díaz M; Miguel M; Triana P
    J Pediatr Adolesc Gynecol; 2019 Dec; 32(6):648-650. PubMed ID: 31330249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
    Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Herrera-Garcia JD; Luque-Valenzuela M; Sanchez-Cano D; Lopez-Gutierrez JC; Ruiz-Villaverde R; Tercedor-Sanchez J
    Clin Genet; 2017 Jan; 91(1):14-21. PubMed ID: 27426476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
    Venot Q; Blanc T; Rabia SH; Berteloot L; Ladraa S; Duong JP; Blanc E; Johnson SC; Hoguin C; Boccara O; Sarnacki S; Boddaert N; Pannier S; Martinez F; Magassa S; Yamaguchi J; Knebelmann B; Merville P; Grenier N; Joly D; Cormier-Daire V; Michot C; Bole-Feysot C; Picard A; Soupre V; Lyonnet S; Sadoine J; Slimani L; Chaussain C; Laroche-Raynaud C; Guibaud L; Broissand C; Amiel J; Legendre C; Terzi F; Canaud G
    Nature; 2018 Jun; 558(7711):540-546. PubMed ID: 29899452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular malformations syndromes: an update.
    Martinez-Lopez A; Salvador-Rodriguez L; Montero-Vilchez T; Molina-Leyva A; Tercedor-Sanchez J; Arias-Santiago S
    Curr Opin Pediatr; 2019 Dec; 31(6):747-753. PubMed ID: 31693582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA vascular overgrowth syndromes: an update.
    Hughes M; Hao M; Luu M
    Curr Opin Pediatr; 2020 Aug; 32(4):539-546. PubMed ID: 32692051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PIK3CA-related overgrowth syndrome (PROS)].
    Venot Q; Canaud G
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum: A brief report.
    Denorme P; Morren MA; Hollants S; Spaepen M; Suaer K; Zutterman N; Labarque V; Legius E; Brems H
    Pediatr Dermatol; 2018 May; 35(3):e186-e188. PubMed ID: 29493003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA-related overgrowth: silver bullets from the cancer arsenal?
    Madsen RR; Semple RK
    Trends Mol Med; 2022 Apr; 28(4):255-257. PubMed ID: 35272946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
    Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
    Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome.
    Forde K; Resta N; Ranieri C; Rea D; Kubassova O; Hinton M; Andrews KA; Semple R; Irvine AD; Dvorakova V
    Orphanet J Rare Dis; 2021 Feb; 16(1):109. PubMed ID: 33639990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the PIK3CA-related overgrowth spectrum (PROS) patient and caregiver journey using a patient-centered approach.
    Rodríguez-Laguna L; Davis K; Finger M; Aubel D; Vlamis R; Johnson C
    Orphanet J Rare Dis; 2022 May; 17(1):189. PubMed ID: 35526022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
    Emrick LT; Murphy L; Shamshirsaz AA; Ruano R; Cassady CI; Liu L; Chang F; Sutton VR; Li M; Van den Veyver IB
    Am J Med Genet A; 2014 Oct; 164A(10):2633-7. PubMed ID: 25044986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
    Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
    Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
    Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
    Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrofacial vascular metameric syndrome is caused by somatic pathogenic variants in
    Sheppard SE; Sanders VR; Srinivasan A; Finn LS; Adams D; Elton A; Amlie-Lefond C; Nelson Z; Dmyterko V; Jensen D; Zenner K; Perkins J; Bennett JT
    Cold Spring Harb Mol Case Stud; 2021 Dec; 7(6):. PubMed ID: 34887309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum.
    Michel ME; Konczyk DJ; Yeung KS; Murillo R; Vivero MP; Hall AM; Zurakowski D; Adams D; Gupta A; Huang AY; Chung BHY; Warman ML
    Clin Genet; 2018 May; 93(5):1075-1080. PubMed ID: 29231959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.